Trials / Completed
CompletedNCT03175549
Medication Development in Alcoholism: Apremilast Versus Placebo
Medication Development for Protracted Abstinence in Alcoholism: Apremilast Versus Placebo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- The Scripps Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary hypotheses under test are that alcohol dependent subjects treated with apremilast will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days. |
| DRUG | Placebo | Identical placebo pills taken orally for 14 days |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2017-06-05
- Last updated
- 2022-09-16
- Results posted
- 2022-09-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03175549. Inclusion in this directory is not an endorsement.